Leptospirosis market seen reaching $790 million by 2030

The global leptospirosis market is projected to rise from $590 million in 2026 to $790 million by 2030, driven by stronger infectious disease surveillance, rapid diagnostics and climate-related flood risks. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Leptospirosis is a public health issue in tropical and subtropical regions, where contaminated water and poor sanitation can speed transmission. - The market outlook points to growing demand for diagnostics, treatment and disease monitoring as governments and health systems focus more on zoonotic and waterborne infections.

What happened: - The Business Research Company released its Leptospirosis Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the market will expand from $0.54 billion in 2025 to $0.59 billion in 2026, a 7.6% CAGR. - The same report projects the market will reach $0.79 billion by 2030, at a 7.8% CAGR. - The release was issued July 2, 2026, from London.

The details: - Leptospirosis is a bacterial zoonotic infection caused by Leptospira species. - People can get infected through contact with water, soil or food contaminated by urine from infected animals, especially rodents. - The bacteria can enter through cuts in the skin or through the eyes, nose or mouth. - Symptoms range from fever, headaches and muscle aches to severe liver, kidney and other organ complications. - Historical growth in the market is tied to rising zoonotic disease incidence in tropical areas, urbanization with poor sanitation, greater exposure to contaminated water, growing livestock and rodent populations in rural areas, and limited early diagnostics in developing countries. - Growth through 2030 is expected to be supported by more infectious disease surveillance spending, wider use of rapid diagnostic technologies, climate-change-linked flooding and water contamination, public health education, and AI-powered epidemic prediction systems. - Emerging trends include genome-based pathogen detection, cloud-based infectious disease monitoring, AI outbreak forecasting, IoT water contamination tracking, and point-of-care rapid test kits for tropical diseases. - The report says North America held the largest share of the leptospirosis market in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region in the coming years. - The analysis also covers South East Asia, Western Europe, Eastern Europe, South America, and the Middle East and Africa. - The Business Research Company also offered a free sample report and the full report online: More information and the full report.

Between the lines: - The forecast suggests leptospirosis is becoming a larger commercial and clinical focus because climate volatility and public health monitoring are pushing earlier detection tools into more markets. - The report's emphasis on AI, IoT and genome-based testing signals a shift from basic surveillance toward more automated and predictive disease management. - The cited zoonotic burden underscores why surveillance budgets and diagnostic demand may keep rising even outside endemic areas.

What's next: - Market growth will likely track continued investment in surveillance, rapid testing and outbreak forecasting tools. - Regional momentum should remain strongest in Asia-Pacific if flooding, sanitation gaps and infectious disease monitoring needs continue to rise. - The report points to more product development around tropical-disease diagnostics and environmental monitoring systems. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards and market hotspot infographics.